Operose Advisors’s Texas Instruments TXN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$261K Sell
875
-1,214
-58% -$337K 0.05% 143
2026
Q1
$406K Buy
2,089
+70
+3% +$14.2K 0.09% 94
2025
Q4
$350K Buy
2,019
+1,138
+129% +$195K 0.08% 104
2025
Q3
$162K Hold
881
0.04% 164
2025
Q2
$183K Hold
881
0.05% 140
2025
Q1
$158K Sell
881
-20
-2% -$3.74K 0.05% 130
2024
Q4
$169K Sell
901
-568
-39% -$114K 0.06% 132
2024
Q3
$303K Buy
1,469
+363
+33% +$72.9K 0.1% 107
2024
Q2
$215K Hold
1,106
0.08% 130
2024
Q1
$193K Hold
1,106
0.07% 156
2023
Q4
$189K Sell
1,106
-264
-19% -$40.9K 0.08% 116
2023
Q3
$218K Buy
1,370
+417
+44% +$71.1K 0.09% 114
2023
Q2
$172K Hold
953
0.08% 92
2023
Q1
$177K Buy
953
+425
+80% +$74.7K 0.09% 82
2022
Q4
$87.2K Hold
528
0.05% 122
2022
Q3
$82K Hold
528
0.05% 120
2022
Q2
$81K Buy
528
+1
+0.2% +$168 0.06% 113
2022
Q1
$97K Buy
527
+95
+22% +$16.8K 0.07% 107
2021
Q4
$81K Buy
+432
New +$82.9K 0.07% 104

Other funds holding TXN

Operose Advisors's TXN Position: Q2 2026 in Review

Operose Advisors reduced its Texas Instruments (TXN) stake by 58% in Q2 2026, selling an estimated $337K and leaving 875 shares worth $261K. The position accounts for 0.05% of the portfolio, ranked #143.

Operose Advisors first reported a position in TXN in Q4 2021 and has held it in 19 quarters since. The position peaked at $406K in Q1 2026. 2,843 funds tracked by Wall St. Rank hold TXN as of Q2 2026.

  • Operose Advisors held 875 shares of Texas Instruments worth $261K as of Q2 2026.
  • Operose Advisors sold 1,214 Texas Instruments shares in Q2 2026, an estimated $337K.
  • Texas Instruments made up 0.05% of Operose Advisors's portfolio in Q2 2026, its #143 holding.
  • Operose Advisors first reported a position in Texas Instruments in Q4 2021 and has held it in 19 quarters since.
  • Operose Advisors's Texas Instruments position peaked at $406K in Q1 2026.
  • 2,843 funds tracked by Wall St. Rank held Texas Instruments as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.